Journals / Cukurova Medical Journal / 2020 / Cilt: 45 - Sayı: 3

Abnormal geometry and hypertrophy of left ventricle in patients with chronic kidney disease

Kronik böbrek hastalarında anormal kalp geometrisi ve sol ventrikül hipertrofisi

Pages
1089–1098
Publication Date
2020-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nontraditional factors such as volume status and nutrition were also crucial for left ventricular remodeling.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to investigate the incidence of left ventricular geometric patterns in patients with chronic kidney disease (CKD).Materials and Methods: A total of 162 patients (100 males) with stage 2–5 CKD were included in the study.
📊
Key Findings & Data:Patient age was between 17 and 79 years.
💡
Conclusion & Impact:Nontraditional factors such as volume status and nutrition were also crucial for left ventricular remodeling.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Left ventricular geometry · Left venticular hypertrophy · Chronic Kidney Disease

Abstract

Purpose: The aim of this study was to investigate the incidence of left ventricular geometric patterns in patients with chronic kidney disease (CKD).Materials and Methods: A total of 162 patients (100 males) with stage 2–5 CKD were included in the study. Patient age was between 17 and 79 years. Left ventricular geometry (LVG) patterns were calculated as left ventricular normal geometry (LVNG), left ventricular concentric remodeling (LVCR), concentric left ventricular hypertrophy (cLVH) and eccentric left ventricular hypertrophy (eLVH) by echocardiographic parameters.Results: The incidence of LVH was 45.1%. LVG patterns were found as follows: eLVH in patients 18(11.1%), cLVH in 42(25.9%), LVCR in 51(31.5%), and LVNG 51(31.5%). LVNG was found 10.38% and 34.27% in CKD stage 2 and dialysis, respectively. LVCR was as high as 62.3% in CKD stage2. cLVH and eLVH were found as 35.92% and 29.13% in stage 5 non-dialysis and dialysis, respectively. There was a relationship between clinical characteristics and LVG as follows age and GFR with LVCR, HbA1C and serum levels of albumin and sodium with cLVH, and age and serum albumin with eLVHConclusions: In our CKD patients, abnormal LVG was found as earlier as CKD stage 2. The incidence of cLVH and eLVH was higher in advanced stages of CKD. Nontraditional factors such as volume status and nutrition were also crucial for left ventricular remodeling.

Özet

Amaç: Bu çalışmanın amacı kronik böbrek hastalığı (KBH) olan hastalarda sol ventrikül geometrisi (SVG) çeşit ve sıklığını araştırmaktır.Gereç ve Yöntem: Evre 2-5 KBH’lı, yaşı 17-79 aralığında, 100’ü erkek toplam 162 hasta çalışmaya dahil edildi. SVG ekokardiyografik parametrelere göre; sol ventrikül normal geometrisi (SVNG), sol ventrikül konsantrik remodelling (SVKR), konsatrik sol ventrikül hipertrofisi (SVKH) ve eksantrik sol ventrikül hipertrofisi (ESVH) olarak hesaplandı.Bulgular: Hastalarımızda SVH sıklığı % 45.1 idi. SVG paternleri: ESVH 18 (% 11.1), KSVH 42 (% 25.9), SVKR 51 (% 31.5) ve SVNG 51 (% 31.5) saptandı. SVNG evre 2 KBH ve diyaliz hastalarında sırasıyla %10.38 ve %34.27 idi. SVKR, evre 2 KBH’da yüksek sıklıkta (% 62.3) saptandı. Non-diyaliz evre 5 KBH ve diyaliz hastalarında KSVH ve ESVH sıklığı sırasıyla % 35.92 ve % 29.13 bulundu. Klinik özellikler ile SVG değerlendirildiğinde; yaş ve GFR SVKR ile, HbA1C, serum albumin ve sodyum seviyeleri KSVH ile, yaş ve serum albumin ESVH ile ilişkiliydi.Sonuç: KBH hastalarımızda, evre 2 KBH aşamasında bile anormal SVG saptandı. KBH’ın ileri evrelerinde KSVH ve ESVH insidansı daha yüksekti. Volum durumu ve beslenme gibi geleneksel olmayan faktörler de sol ventrikül yeniden şekillenmesinde önemliydi.

🔖

Cite This Article

KAYA, B., PAYDAS, S., SEYREK, N., BALAL, M., KARAYAYLALI, İ. (2020). Abnormal geometry and hypertrophy of left ventricle in patients with chronic kidney disease. Cukurova Medical Journal, Cilt: 45 - Sayı: 3, 1089–1098. https://ajindex.com/articles/110794

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:16-23
  2. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-45
  3. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143- 421
  4. Ravarotto V, Simioni F, Pagnin E, Davis PA, Calo LA. Oxidative stress - chronic kidney disease - cardiovascular disease: A vicious circle. Life Sci. 2018;210:125-31
  5. Ardahanli I, Celik M. Can myocardial performance index predict early cardiac risks in erectile dysfunction? Aging Male 2020; doi: 10.1080/13685538.2020.1768367:1-7
  6. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2003;16:85-94
  7. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492-8
  8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6
  9. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis. 2002;40:1230-9
  10. Chirakarnjanakorn S, Navaneethan SD, Francis GS, Tang WH. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. Int J Cardiol. 2017;232:12-23
  11. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-7
  12. Malyala R, Rapi L, Nash MM, Prasad GVR. Pretransplant left ventricular geometry and major adverse cardiovascular events after kidney transplantation. Ann Transplant. 2019;24:100-7
  13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of